|
12 Sep 2025 |
Fortis Healthcare
|
Consensus Share Price Target
|
965.95 |
983.07 |
- |
1.77 |
buy
|
|
|
|
|
09 Feb 2024
|
Fortis Healthcare
|
Prabhudas Lilladhar
|
965.95
|
480.00
|
434.95
(122.08%)
|
Target met |
Buy
|
|
|
|
|
21 Nov 2023
|
Fortis Healthcare
|
Geojit BNP Paribas
|
965.95
|
390.00
|
372.40
(159.39%)
|
Target met |
Hold
|
|
|
|
|
12 Nov 2023
|
Fortis Healthcare
|
Prabhudas Lilladhar
|
965.95
|
400.00
|
358.40
(169.52%)
|
Target met |
Buy
|
|
|
|
|
17 Aug 2023
|
Fortis Healthcare
|
Geojit BNP Paribas
|
965.95
|
340.00
|
318.05
(203.71%)
|
Target met |
Hold
|
|
|
|
|
08 Aug 2023
|
Fortis Healthcare
|
ICICI Securities Limited
|
965.95
|
390.00
|
323.90
(198.22%)
|
Target met |
Buy
|
|
|
Fortis’s Q1 hospital EBITDA performance was disappointing (margins at 15.2% vs our estimate of 16.5% and Q4FY23’s 16.4%). New bed addition took a toll on margins of Mulund hospital (less than 10% vs 20-25% earlier) while seasonality at a few facilities led to a drop in overall occupancy to 64% vs 65% in Q1FY23 and 67% in Q4FY23.
|
|
22 Jun 2023
|
Fortis Healthcare
|
Prabhudas Lilladhar
|
965.95
|
365.00
|
309.20
(212.40%)
|
Target met |
Buy
|
|
|
|
|
30 May 2023
|
Fortis Healthcare
|
Geojit BNP Paribas
|
965.95
|
316.00
|
281.05
(243.69%)
|
Target met |
Accumulate
|
|
|
|
|
25 May 2023
|
Fortis Healthcare
|
ICICI Securities Limited
|
965.95
|
360.00
|
287.60
(235.87%)
|
Target met |
Buy
|
|
|
Fortis Healthcare’s (FHL) hospital business grew strong 6.6% QoQ driven by ARPOB improvement, specialty and payor mix. Most of its key hospitals reported strong sequential growth.
|
|
24 May 2023
|
Fortis Healthcare
|
Prabhudas Lilladhar
|
965.95
|
330.00
|
287.60
(235.87%)
|
Target met |
Buy
|
|
|
|
|
13 Feb 2023
|
Fortis Healthcare
|
Prabhudas Lilladhar
|
965.95
|
360.00
|
272.25
(254.80%)
|
Target met |
Buy
|
|
|
|
|
15 Nov 2022
|
Fortis Healthcare
|
ICICI Securities Limited
|
965.95
|
331.00
|
301.50
(220.38%)
|
Target met |
Accumulate
|
|
|
Fortis Healthcare’s (FHL) Q2FY23 performance was broadly in line with our estimates. Revenues grew 9.9% YoY to Rs16.0bn (I-Sec: Rs16.2bn) with hospital segment growing 18.1% YoY.
|
|
14 Nov 2022
|
Fortis Healthcare
|
Prabhudas Lilladhar
|
965.95
|
360.00
|
301.50
(220.38%)
|
Target met |
Buy
|
|
|
|
|
23 Sep 2022
|
Fortis Healthcare
|
ICICI Securities Limited
|
965.95
|
299.00
|
265.55
(263.75%)
|
Target met |
Accumulate
|
|
|
The Supreme Court of India (SC) has announced its judgement in the Daiichi Sankyo-Fortis-IHH case.
|
|
10 Aug 2022
|
Fortis Healthcare
|
ICICI Securities Limited
|
965.95
|
299.00
|
269.15
(258.89%)
|
Target met |
Accumulate
|
|
|
Fortis Healthcare’s (FHL) Q1FY23 performance was broadly in line with our estimates. Revenues grew 5.5% YoY to Rs14.9bn (I-Sec: Rs14.5bn) with hospital segment growing 18.5% YoY.
|
|
09 Aug 2022
|
Fortis Healthcare
|
Prabhudas Lilladhar
|
965.95
|
330.00
|
267.30
(261.37%)
|
Target met |
Buy
|
|
|
|
|
27 May 2022
|
Fortis Healthcare
|
Prabhudas Lilladhar
|
965.95
|
330.00
|
244.70
(294.75%)
|
|
Buy
|
|
|
|
|
01 Dec 2021
|
Fortis Healthcare
|
Ashika Research
|
965.95
|
325.00
|
286.60
(237.04%)
|
Target met |
Buy
|
|
|
points. FHL has a long and established track record having favourable hospital maturity mix profile with large network of healthcare facilities. It has presence across various healthcare verticals, including secondary, tertiary care and diagnostics. Fortis has operations in India, United Arab Emirates (UAE) & Sri Lanka. With its...
|
|
01 Nov 2019
|
Fortis Healthcare
|
Ventura
|
965.95
|
|
150.85
(540.34%)
|
|
Buy
|
|
|
Large hospital chain at a significant discount to market leader Apollo Hospitals
|
|
02 Apr 2018
|
Fortis Healthcare
|
Way2Wealth
|
965.95
|
|
127.90
(655.24%)
|
|
|
|
|
Fortis Healthcare Limited is a leading integrated healthcare delivery service provider in India. The healthcare verticals of the company primarily comprise of hospitals, diagnostics and day care specialty facilities. Currently, the company...
|
|
16 Mar 2018
|
Fortis Healthcare
|
ICICI Securities Limited
|
965.95
|
195.00
|
155.55
(520.99%)
|
|
Buy
|
|
|
|